These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31932911)

  • 1. Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort.
    Carnero Contentti E; Daccach Marques V; Soto de Castillo I; Tkachuk V; Ariel B; Castillo MC; Cristiano E; Diégues Serva GB; Dos Santos AC; Finkelsteyn AM; López PA; Patrucco L; Molina O; Pettinicchi JP; Toneguzzo V; Caride A; Rojas JI
    J Neurol; 2020 May; 267(5):1260-1268. PubMed ID: 31932911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder.
    Hu Y; Sun Q; Yi F; Yao L; Tian Y; Tang H; Luo M; Xie N; Wang Z; Liao X; Zhou L; Xu H; Zhou Y
    Front Immunol; 2022; 13():1056944. PubMed ID: 36569880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Late-onset neuromyelitis optica spectrum disorder: The importance of autoantibody serostatus.
    Sepulveda M; Delgado-García G; Blanco Y; Sola-Valls N; Martinez-Lapiscina EH; Armangué T; Montejo C; Pulido-Valdeolivas I; Martinez-Hernandez E; Ariño H; Escudero D; Ruiz-García R; Llufriu S; Dalmau J; Graus F; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2019 Nov; 6(6):. PubMed ID: 31471461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
    Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
    Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder.
    Cai LJ; Zhang Q; Zhang Y; Chen HX; Shi ZY; Du Q; Zhou HY
    Mult Scler Relat Disord; 2020 Nov; 46():102515. PubMed ID: 33032051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population.
    Silveira F; Pappolla A; Sánchez F; Marques VD; de Castillo IS; Tkachuk V; Caride A; Castillo MC; Cristiano E; Cruz CA; Diégues Serva GB; Dos Santos AC; Moreira CL; López PA; Patrucco L; Molina O; Pettinicchi JP; Carnero Contentti E; Rojas JI
    Mult Scler Relat Disord; 2020 Jul; 42():102049. PubMed ID: 32251869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients.
    Carnero Contentti E; Soto de Castillo I; Daccach Marques V; López PA; Antunes Barreira A; Armas E; de Aquino Cruz C; Rubstein A; Lavigne Moreira C; Molina OM; Soto A; Tkachuk V
    Mult Scler Relat Disord; 2018 Feb; 20():109-114. PubMed ID: 29367170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Very late onset neuromyelitis optica spectrum disorders.
    Nakahara K; Nakane S; Nagaishi A; Narita T; Matsuo H; Ando Y
    Eur J Neurol; 2021 Aug; 28(8):2574-2581. PubMed ID: 33960076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis Optica spectrum disorders in Argentina: A hospital-based study.
    Villa AM; Manin A; Seimandi C; Finkelsteyn AM; Ramos G; Tenembaum S
    Mult Scler Relat Disord; 2023 Nov; 79():105018. PubMed ID: 37806234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute optic nerve lesions in first-ever NMOSD-related optic neuritis using conventional brain MRI: A Latin American multicenter study.
    Carnero Contentti E; Delgado-García G; López PA; Criniti J; Pettinicchi JP; Correa-Díaz EP; Soto de Castillo I; Daccach Marques V; Tkachuk V; Cristiano E; Serva Braga Diéguez G; Dos Santos AC; Castillo MC; Patrucco L; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Caride A; Rojas JI
    Mult Scler Relat Disord; 2020 Nov; 46():102558. PubMed ID: 33032052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders with and without associated autoimmune diseases.
    Carnero Contentti E; López PA; Pettinicchi JP; Tkachuk V; Daccach Marques V; de Castillo IS; Cristiano E; Patrucco L; Caride A; Rojas JI
    Neurol Sci; 2023 May; 44(5):1731-1737. PubMed ID: 36645533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study.
    Ibis SC; Omaira M; Arnoldo S; Elizabeth A; Sandra M; Carlota CM; Elizabeth C; Laura V; Rosalba L; Oscar V; Luisa DM; Nahir A; Hernandez F
    Mult Scler Relat Disord; 2021 Jan; 47():102652. PubMed ID: 33279797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuromyelitis optica spectrum disorders with a benign course. Analysis of 544 patients.
    Lana-Peixoto MA; Talim NC; Callegaro D; Marques VD; Damasceno A; Becker J; Gonçalves MVM; Sato H;
    Mult Scler Relat Disord; 2023 Jul; 75():104730. PubMed ID: 37156036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.
    Mao Z; Yin J; Zhong X; Zhao Z; Qiu W; Lu Z; Hu X
    BMC Neurol; 2015 Sep; 15():160. PubMed ID: 26337073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD.
    Carnero Contentti E; Delgado-García G; Criniti J; López PA; Pettinicchi JP; Cristiano E; Miguez J; Correa-Díaz EP; Álvarez Pucha MO; Miño Zambrano JE; Gómez-Figueroa E; Rivas-Alonso V; Flores-Rivera J; Tkachuk V; Caride A; Rojas JI
    Front Immunol; 2021; 12():628024. PubMed ID: 33717149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.